IP Verse

Extended, High Dose Vegf Antagonist Regimens For Treatment Of Angiogenic Eye Disorders

Patent No. EP4185318 (titled "Extended, High Dose Vegf Antagonist Regimens For Treatment Of Angiogenic Eye Disorders") was filed by Bayer Healthcare on May 16, 2022. The application was issued on Sep 3, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOULT WADE TENNANTJun 3, 2026BOULT WADE TENNANT
EIPJun 3, 2026EIP
KIVIALJun 3, 2026PETRAZ
AMGENJun 2, 2026UEXKULL & STOLBERG
BISCHOF & PARTNER PARTNERSCHAFTSGE SELLSCHAFT OLIVER BISCHOFJun 2, 2026-
KILBURN & STRODEJun 2, 2026LEONARD
NEUEFEINDJun 2, 2026MAIWALD
ADVANZ PHARMA SERVICES UKJun 1, 2026POTTER CLARKSON
INTAS PHARMACEUTICALSJun 1, 2026TER MEER STEINMEISTER & PARTNER
SANDOZJun 1, 2026MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4185318

BAYER HEALTHCARE
Application Number
EP22728724A
Filing Date
May 16, 2022
Status
Granted And Under Opposition
Aug 1, 2025
Publication Date
Sep 3, 2025
External Links
Slate, Register , Google Patents